BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 38760351)

  • 1. Enhancement of Chemotherapy Efficacy in Cervical Cancer via MAPK Pathway Inhibition by Osimertinib.
    Hu Y; Hu C
    Cancer Invest; 2024 May; 42(5):425-434. PubMed ID: 38818695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted ferritinophagy in gastrointestinal cancer: from molecular mechanisms to implications.
    Feng Z; Luan M; Zhu W; Xing Y; Ma X; Wang Y; Jia Y
    Arch Toxicol; 2024 Jul; 98(7):2007-2018. PubMed ID: 38602537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous adverse events following treatment with third-generation EGFR tyrosine kinase inhibitors.
    Li Pomi F; Vaccaro F; Borgia F; Irrera N; Vaccaro M
    Ital J Dermatol Venerol; 2024 Apr; 159(2):212-214. PubMed ID: 38261309
    [No Abstract]   [Full Text] [Related]  

  • 4. Ferritinophagy mediates adaptive resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Wang H; Hu Q; Chen Y; Huang X; Feng Y; Shi Y; Li R; Yin X; Song X; Liang Y; Zhang T; Xu L; Dong G; Jiang F
    Nat Commun; 2024 May; 15(1):4195. PubMed ID: 38760351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells.
    Criscione SW; Martin MJ; Oien DB; Gorthi A; Miragaia RJ; Zhang J; Chen H; Karl DL; Mendler K; Markovets A; Gagrica S; Delpuech O; Dry JR; Grondine M; Hattersley MM; Urosevic J; Floc'h N; Drew L; Yao Y; Smith PD
    NPJ Precis Oncol; 2022 Dec; 6(1):95. PubMed ID: 36575215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PINK1-Mediated Mitophagy Promotes Oxidative Phosphorylation and Redox Homeostasis to Induce Drug-Tolerant Persister Cancer Cells.
    Li Y; Chen H; Xie X; Yang B; Wang X; Zhang J; Qiao T; Guan J; Qiu Y; Huang YX; Tian D; Yao X; Lu D; Koeffler HP; Zhang Y; Yin D
    Cancer Res; 2023 Feb; 83(3):398-413. PubMed ID: 36480196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiphase coalescence mediates Hippo pathway activation.
    Wang L; Choi K; Su T; Li B; Wu X; Zhang R; Driskill JH; Li H; Lei H; Guo P; Chen EH; Zheng Y; Pan D
    Cell; 2022 Nov; 185(23):4376-4393.e18. PubMed ID: 36318920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An early origin of iron-sulfur cluster biosynthesis machineries before Earth oxygenation.
    Garcia PS; D'Angelo F; Ollagnier de Choudens S; Dussouchaud M; Bouveret E; Gribaldo S; Barras F
    Nat Ecol Evol; 2022 Oct; 6(10):1564-1572. PubMed ID: 36109654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse.
    Nie M; Chen N; Pang H; Jiang T; Jiang W; Tian P; Yao L; Chen Y; DeBerardinis RJ; Li W; Yu Q; Zhou C; Hu Z
    J Clin Invest; 2022 Oct; 132(20):. PubMed ID: 36048538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells.
    Tan Y; Li J; Zhao G; Huang KC; Cardenas H; Wang Y; Matei D; Cheng JX
    Nat Commun; 2022 Aug; 13(1):4554. PubMed ID: 35931676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.
    Noronha A; Belugali Nataraj N; Lee JS; Zhitomirsky B; Oren Y; Oster S; Lindzen M; Mukherjee S; Will R; Ghosh S; Simoni-Nieves A; Verma A; Chatterjee R; Borgoni S; Robinson W; Sinha S; Brandis A; Kerr DL; Wu W; Sekar A; Giri S; Chung Y; Drago-Garcia D; Danysh BP; Lauriola M; Fiorentino M; Ardizzoni A; Oren M; Blakely CM; Ezike J; Wiemann S; Parida L; Bivona TG; Aqeilan RI; Brugge JS; Regev A; Getz G; Ruppin E; Yarden Y
    Cancer Discov; 2022 Nov; 12(11):2666-2683. PubMed ID: 35895872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coordinated Transcriptional and Catabolic Programs Support Iron-Dependent Adaptation to RAS-MAPK Pathway Inhibition in Pancreatic Cancer.
    Ravichandran M; Hu J; Cai C; Ward NP; Venida A; Foakes C; Kuljanin M; Yang A; Hennessey CJ; Yang Y; Desousa BR; Rademaker G; Staes AAL; Cakir Z; Jain IH; Aguirre AJ; Mancias JD; Shen Y; DeNicola GM; Perera RM
    Cancer Discov; 2022 Sep; 12(9):2198-2219. PubMed ID: 35771494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron-Sulfur Cluster Proteins.
    Santana-Codina N; Del Rey MQ; Kapner KS; Zhang H; Gikandi A; Malcolm C; Poupault C; Kuljanin M; John KM; Biancur DE; Chen B; Das NK; Lowder KE; Hennessey CJ; Huang W; Yang A; Shah YM; Nowak JA; Aguirre AJ; Mancias JD
    Cancer Discov; 2022 Sep; 12(9):2180-2197. PubMed ID: 35771492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.
    Goodwin PJ; Chen BE; Gelmon KA; Whelan TJ; Ennis M; Lemieux J; Ligibel JA; Hershman DL; Mayer IA; Hobday TJ; Bliss JM; Rastogi P; Rabaglio-Poretti M; Mukherjee SD; Mackey JR; Abramson VG; Oja C; Wesolowski R; Thompson AM; Rea DW; Stos PM; Shepherd LE; Stambolic V; Parulekar WR
    JAMA; 2022 May; 327(20):1963-1973. PubMed ID: 35608580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic reprogramming in cholangiocarcinoma.
    Raggi C; Taddei ML; Rae C; Braconi C; Marra F
    J Hepatol; 2022 Sep; 77(3):849-864. PubMed ID: 35594992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.
    Cooper AJ; Sequist LV; Lin JJ
    Nat Rev Clin Oncol; 2022 Aug; 19(8):499-514. PubMed ID: 35534623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferroptosis at the intersection of lipid metabolism and cellular signaling.
    Liang D; Minikes AM; Jiang X
    Mol Cell; 2022 Jun; 82(12):2215-2227. PubMed ID: 35390277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copper induces cell death by targeting lipoylated TCA cycle proteins.
    Tsvetkov P; Coy S; Petrova B; Dreishpoon M; Verma A; Abdusamad M; Rossen J; Joesch-Cohen L; Humeidi R; Spangler RD; Eaton JK; Frenkel E; Kocak M; Corsello SM; Lutsenko S; Kanarek N; Santagata S; Golub TR
    Science; 2022 Mar; 375(6586):1254-1261. PubMed ID: 35298263
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.